Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates
Solid Biosciences(US:SLDB) Globenewswire·2025-08-13 04:07- Duchenne (SGT-003): 15 participants dosed in the Phase 1/2 INSPIRE DUCHENNE trial and dosing remains ongoing; On track to discuss regulatory pathways with U.S. FDA in Q4 2025 - - FA (SGT-212): Phase 1b trial initiation expected in Q4 2025 - - CPVT (SGT-501): Phase 1b trial initiation expected in Q4 2025 - - Capsids (AAV-SLB101): Over 25 agreements or licenses with academic labs, institutions and corporations for the use of AAV-SLB101 have been executed - - Cash: Company ended Q2 2025 with $268.1 million i ...